Combination Chemoembolization and Radiofrequency Ablation for Hepatocellular Carcinoma Greater Than 3 cm (TACE-RFA)
Procedure: chemoembolization ,Radiofrequency ablation
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Single Blind
Primary Purpose: Treatment
|Official Title:||Phase 1 Study of Combination Chemoembolization and Radiofrequency Ablation for Hepatocellular Carcinoma Greater Than 3 cm|
- overall survival [ Time Frame: 5 years ]
- tumor response [ Time Frame: 1-6 months ]
|Study Start Date:||January 2001|
|Study Completion Date:||December 2006|
To assess whether the effectiveness of a combination of transcatheter arterial chemoembolization(TACE) and radiofrequency ablation(RFA) is superior to TACE and RFA alone in treatment of patients with hepatocellular carcinoma(HCC)greater than 3 cm and to analyze the factors affecting the outcomes.
The patients with HCC of 3 or fewer lesions, each 3cm greater in diameter entered this randomized controlled trial. The primary end point was survival, and the secondary end points were tumor response.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00479050
|Study Chair:||Wang Qi Liang, MD,PhD||Dept. of Radiology|